Former Armo Bio Exec Leveque Joins Synthorx as Chief Medical Officer

Xconomy San Diego — 

Synthorx has appointed Joseph Leveque to serve as chief medical officer of the San Diego biotech. Leveque most recently worked at Redwood City, CA-based cancer drug developer Armo Biosciences, which was acquired by Eli Lilly (NYSE: LLY) for $1.6 billion earlier this year. Leveque’s experience also includes senior roles at EMD Serono, Bristol-Myers Squibb (NYSE: BMY), and Onyx Pharmaceuticals. In April, Synthorx raised $63 million in a Series C financing round to advance Synthorin IL-2, its version of the cancer drug interleukin 2, into clinical testing.